Latest Research And Development News

BPH Global’s Indonesian unit has locked in a four-year MoU with ITBM to integrate student-driven operations and research at its Takalar coastal seaweed site, setting the stage for scaled commercial development and local collaboration.

Andromeda Metals has secured a $1.66 million cash refund from the Australian Government's R&D Tax Incentive program, reflecting $3.4 million of eligible expenditure tied to its Great White Project.

Arovella Therapeutics undergoes a major board overhaul and CEO resignation following a shareholder push, as the company embarks on a strategic review of its cell therapy platform.

Nexsen Limited teams with Universiti Malaya to launch a joint research facility aiming to develop a rapid biosensor detecting E. coli and Salmonella simultaneously, addressing a critical food safety gap in Southeast Asia.

Brazilian Critical Minerals (ASX: BCM) has locked in pre-approval under Australia’s R&D Tax Incentive for its Ema Rare Earth Project, including critical overseas activities in Brazil. This reduces regulatory uncertainty and supports funding efficiency for advancing the project’s development.

Recce Pharmaceuticals bolsters its clinical and commercial pipeline with a $5.3 million AUD R&D tax rebate, a second U.S. Army research agreement for its RECCE 327 Gel, and a key patent granted in Brazil, while progressing Phase 3 trials in Indonesia.

ReNerve Limited reports a 79% jump in quarterly sales, secures key Asia-Pacific approvals, and progresses its nerve repair pipeline with the NervAlign Nerve Guide Matrix entering Stage 3 development.

Marquee Resources has significantly increased its Mt Clement inferred antimony resource and is advancing drilling and strategic partnerships to develop its flagship project.

Percheron Therapeutics has secured $2.2 million through an entitlement offer to fund the next stage of its HMBD-002 oncology program, with manufacturing underway and key data presentations lined up at major cancer conferences.

Racura Oncology reported robust progress in Q3 FY2026, including launching a key lung cancer trial and unveiling a novel blood test for cardioprotection, supported by a solid $19.38 million cash position.

BlinkLab has completed onboarding all clinical sites for its pivotal FDA autism trial, enrolled the first participant, and launched a nationwide autism screening program in Morocco. A recent A$17.7 million capital raise will fund further trials and expansion into ADHD diagnostics.

Beetaloo Energy has bolstered its financial footing with a $66.3 million equity placement and a $15.4 million R&D tax refund, underpinning key developments at the Carpentaria Gas Plant and local frac sand project.